PMGC Holdings Inc. announced that its wholly owned subsidiary, NorthStrive Biosciences Inc., has executed a definitive, exclusive license agreement with Modulant Biosciences LLC. The agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize NorthStrive's EL-22 and EL-32 assets for animal health applications worldwide, excluding the Republic of Korea. Modulant will be responsible for all development, manufacturing, regulatory, and commercialization activities related to the licensed products. The agreement covers issued patents, pending patent applications, and associated proprietary know-how for EL-22 and EL-32.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-015003), on February 11, 2026, and is solely responsible for the information contained therein.